Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$84,074.00-0.68%ETH$2,690.23-0.10%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
Galmed Pharmaceuticals Ltd. logo

NASDAQ · GLMD

Galmed Pharmaceuticals Ltd.

Healthcare · Biotechnology

$4.63

Up+$0.81 (+21.05%)

Updated Sep 25, 2026, 11:30 PM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.64M
P/E ratio
-0.47
Dividend yield
0.00%
52-week range
$0.41 – $5.45
Volume
303.32K
Avg. volume
2.06M

Price performance

GLMD price history

1M range · 8 trading sessions · Daily adjusted prices

GLMD closed at $4.63 after 8 trading sessions, up 11.16% for the selected period.

Last close
$4.63
Period change
+11.16%
Period low
$3.83
Period high
$4.63
Daily close
View OHLC price history
GLMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$3.91$4.63$3.82$4.63303.32K
Sep 8, 2026$3.81$3.96$3.74$3.82514.85K
Sep 4, 2026$4.0749$4.23$3.88$3.884.1K
Sep 3, 2026$4.05$4.062$3.90$3.9212.13K
Sep 2, 2026$3.97$4.223$3.94$4.11915.62K
Sep 1, 2026$4.07$4.12$3.8176$3.92524.18K
Aug 31, 2026$4.04$4.16$4.03$4.127.21K
Aug 28, 2026$4.16$4.26$3.9588$4.1655.37K

Latest GLMD news

The latest Smart Investors Daily articles mentioning GLMD.

Stock researchCompany · Overview

GLMD research

Overview

Company profile and research snapshot.

Company profile

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GLMD recent ratings
DateFirmRatingTarget
Apr 4, 2025Maxim GroupHold—
Jul 24, 2023Maxim GroupBuy—
Aug 8, 2022Maxim GroupHold—
Aug 8, 2022Canaccord GenuityHold—
May 18, 2022Raymond JamesMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced a corporate rebranding to Eocene Ltd. ("EoCene"), a change in the trading symbol of the Company on the Nasdaq Capital Market to "EOCN" and a new website www.EOCN.com. The name change and trading symbol change are expected to become effective on the Nasdaq Capital Market on September 10, 2026.

Benzinga · Aug 17, 2026

Galmed Pharmaceuticals Announces Results From Pre-Clinical Study Of Combination Of Aramchol And Xtandi For Prostatic Cancer; New Data Demonstrated That A Combination Of Aramchol With Enzalutamide Resulted In Three- To Four-Fold Increase In Cell Death Compared With Enzalutamide As A Single Agent

Xtandi (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By